LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

4.25 1.92

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.05

Max

4.3

Galvenie mērījumi
By Trading Economics
Ienākumi	-8.5M -35M
Darbinieki	106
EBITDA	-11M -37M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+97.37% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 12. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	126M 290M
Iepriekšējā atvēršanas cena	2.33
Iepriekšējā slēgšanas cena	4.25

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

1.23 / 1.45 Atbalsts un pretestība

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. maijs 23:58 UTC

Peļņas

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

2026. g. 7. maijs 22:57 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

2026. g. 7. maijs 23:52 UTC

Peļņas

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

2026. g. 7. maijs 23:45 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 7. maijs 23:39 UTC

Tirgus saruna

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

2026. g. 7. maijs 23:28 UTC

Tirgus saruna

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

2026. g. 7. maijs 23:11 UTC

Peļņas

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

2026. g. 7. maijs 23:06 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

2026. g. 7. maijs 23:05 UTC

Peļņas

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

2026. g. 7. maijs 23:04 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

2026. g. 7. maijs 23:03 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

2026. g. 7. maijs 23:02 UTC

Peļņas

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

2026. g. 7. maijs 23:00 UTC

Tirgus saruna

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. maijs 22:45 UTC

Tirgus saruna

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

2026. g. 7. maijs 22:42 UTC

Peļņas

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

2026. g. 7. maijs 22:33 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

2026. g. 7. maijs 22:32 UTC

Peļņas

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

2026. g. 7. maijs 22:31 UTC

Peļņas

Macquarie: 68% of FY Income From International >MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

2026. g. 7. maijs 22:30 UTC

Peļņas

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

2026. g. 7. maijs 22:29 UTC

Peļņas

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

2026. g. 7. maijs 22:28 UTC

Peļņas

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

2026. g. 7. maijs 22:27 UTC

Peļņas

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

2026. g. 7. maijs 22:26 UTC

Peļņas

Macquarie to End Share Buyback Extended in November>MQG.AU

2026. g. 7. maijs 22:25 UTC

Peļņas

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

97.37% augšup

Prognoze 12 mēnešiem

Vidējais 8.25 USD 97.37%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

1.23 / 1.45Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.